Views & Analysis | Perspectives on pharma industry issues

R&D

Beyond proof of concept: Alzheimer’s and the next chapter of...

Research has demonstrated that some individuals at elevated risk of Alzheimer's disease can be identified before symptoms emerge.

Digital

The augmented marketer: Fusing AI and human expertise in lif...

Predictive AI is not replacing human expertise, but augmenting it.

Digital

Trends & Insights: March 2026 – A pharmaphorum industry repo...

In March's Trends & Insights report, we look across the life sciences industry at the trends behind the headline news for what's also happening.

R&D

Changing Faces: Board of Directors and Advisory Boards, Marc...

Board‑level appointments this month were thick and fast, with six Boards adding new faces as Chairperson.

Market Access

Health, growth & renewal: ABPI 2026 looks to UK’s future

The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.

R&D

How pharma can incorporate AI into research

The use of artificial intelligence (AI) in the biopharma industry has the potential to revolutionise drug discovery and development, as well as improve patient care.

Digital

Newel Health scores $2.5M from MJFF for Parkinson’s app

Newel Health has been awarded a $2.5 million USD grant from the Michael J.

R&D

Was the response to monkeypox a success?

The viral disease that infected a number of people across various countries caused significant alarm for its potential to spread rapidly.

Sales & Marketing

pharmaphorum podcast Episode 257, John Holodnak, Occam

A philosophical look at market turn in the Age of AI, with J...

John Holodnak, co-founder of Occam, discusses how AI is beginning to reshape career paths across life sciences.

Sales & Marketing

Changing Faces: Agency, consultancy, and investor, March 202...

March saw a handful of noteworthy hires in the agency, consultancy, and investor spaces.

Digital

The augmented marketer: Fusing AI and human expertise in lif...

Predictive AI is not replacing human expertise, but augmenting it.

Digital

Trends & Insights: March 2026 – A pharmaphorum industry repo...

In March's Trends & Insights report, we look across the life sciences industry at the trends behind the headline news for what's also happening.

Market Access

Health, growth & renewal: ABPI 2026 looks to UK’s future

The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.

Market Access

The companies shaping the UK’s commercial landscape

Which companies are working with the government to implement the US-UK pharmaceutical trade agreement?

Oncology

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Oncology

From preclinical toxicology to clinical safety: The path for...

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Patients

pharmaphorum podcast Episode 256, Dean Erhardt, D2 Solutions

Providing patient access to new therapies, with Dean Erhardt

Dean Erhardt, founder of D2 Solutions, discusses patient access today versus the state of patient access tomorrow.

Patients

Pharmacist with patient and prescription

From access to advocacy: Turning patients into brand champio...

Done right, DTP is not just filling scripts. It is building loyalty that turns satisfied patients into lifelong advocates.

Patients

Anatomical graphic concept of a liver in 3D

Rewriting the MASLD playbook

Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.

Beyond proof of concept: Alzheimer’s and the next chapter of...

The augmented marketer: Fusing AI and human expertise in lif...

Trends & Insights: March 2026 – A pharmaphorum industry repo...

Changing Faces: Board of Directors and Advisory Boards, Marc...

Health, growth & renewal: ABPI 2026 looks to UK’s future

How pharma can incorporate AI into research

Newel Health scores $2.5M from MJFF for Parkinson’s app

Was the response to monkeypox a success?

A philosophical look at market turn in the Age of AI, with J...

Changing Faces: Agency, consultancy, and investor, March 202...

The augmented marketer: Fusing AI and human expertise in lif...

Trends & Insights: March 2026 – A pharmaphorum industry repo...

Health, growth & renewal: ABPI 2026 looks to UK’s future

The companies shaping the UK’s commercial landscape

From promise to practice: What must happen next for genetic ...

LSX2026: Addressing adult eye cancer, with Roi Raz

From preclinical toxicology to clinical safety: The path for...

Providing patient access to new therapies, with Dean Erhardt

From access to advocacy: Turning patients into brand champio...

Rewriting the MASLD playbook

Beyond proof of concept: Alzheimer’s and the next chapter of...

Changing Faces: Board of Directors and Advisory Boards, Marc...

How automation can drive a competitive advantage for CROs & ...

UCB buys cell therapy biotech Candid for $2bn upfront

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks